BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
See W.A., chapman P.H. (1987)<br />
Hepatin prevention of tumor cell adherence and implantation on injured urothelial surfaces .<br />
J, Urol ., 138: 182-186<br />
Sharpe J.R., Duffy c., chin J.L. (1993)<br />
Intrarenal Bacillus Calmette Guérin therapy for upper urinary tract carcinoma in situ<br />
J . Urol ., 149: 457-460<br />
Smith G.V., Morse P.A.Jr., Deraps G.D. (1973)<br />
Immunotherpy of patients with cancer<br />
Surgery; 74: 59-68<br />
Smith J.A., Labasky R.F., cockett A.t.k., Fracchia J.A., Montie J.e.,<br />
Rowland R.G. (1999)<br />
Bladder cancer clinical guidelines panel summary report on the management of non muscle<br />
invasive bladder cancer (Stages Ta, T1 and TIS)<br />
J . Urol ., 162: 1697-1701<br />
Studer U.e., casanova G., kraft R., Zingg e.J. (1989)<br />
Percutaneous Bacillus Calmette-Guérin Perfusion Of The Upper Urinary Tract for<br />
Carcinoma In Situ<br />
J . Urol ., 142: 975-977<br />
Sylvester R., van der Meijden APM., oosterlink W., casetta G., Hoeltl W.,<br />
Bono A. (2003)<br />
The side effects of Bacillus Calmette Guérin in the treatment of Ta T1 bladder cancer do not<br />
predict its efficacy: Results from an EORTC genitourinary group phase III trial<br />
Eur . Urol . (Suppl): 2, 1: Abstr . 753<br />
Sylvester-RJ, Van der Meijden-APM, Lamm-DL (2002)<br />
Intravesical Bacillus Calmette-Guérin Reduces the risk of Progression in Patients with<br />
superficial Bladder Cancer: A meta Analysis of the Published Results of Randomized<br />
Clinical Trials .<br />
J . Urol . ,168, 1964-1970<br />
tavolini I.M., Gardiman M., Benedetto G., Bassi P. (2002)<br />
Unmanageable fever and granulomatous renal mass after intracavitary upper urinary tract<br />
Bacillus Calmette-Guérin therapie<br />
J . Urol ., 167: 244-245<br />
tawfiek e.R., Bagley D.H. (1997)<br />
Uppertract transitional cell carcinoma<br />
Urology, 50 (3): 321-329<br />
thanhäuser A., Böhle A., Flad H.D., ernst M., Mattern t., Ulmer A.J. (1993)<br />
Induction of Bacillus Calmette-Guérin-activated killer cells from human peripheral blood<br />
mononuclear cells against human bladder carcinoma cells lines in vitro<br />
Cancer Immunol, Immunother ., 37: 105-111<br />
Utz D.c., Farrow G.M., Rife c.c., Segura J.W., Zincke M. (1980)<br />
Carcinoma in situ of the bladder<br />
Cancer, 45: 1842-1848<br />
Utz D.c., Farrow G.M. (1984)<br />
Carcinoma in situ of the urinary tract<br />
Urol . Clin . N . Am ., 11:735-735<br />
Vegt P.D.J., Witjes A., Witjes W.P.J., Doesburg W.H., Debruyne M.J., van der<br />
Meijden A.P.M. (1995)<br />
A randomized study of intravesical Mitomycin C, Bacillus Calmette-Guérin Tice and Bacillus<br />
Calmette-Guérin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of<br />
the bladder<br />
J . Urol ., 153: 929-933<br />
71
Change language